{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:55:18Z","timestamp":1792792518880,"version":"4.5.0"},"reference-count":235,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12072-021-10276-6","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:16:43Z","timestamp":1643933803000},"page":"1-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis"],"prefix":"10.1007","volume":"16","author":[{"given":"Hong","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cumali","family":"Efe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook-Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumichi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Mo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawesak","family":"Tanwandee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino A.","family":"Gani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Payawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barjesh C.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yokosuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Kadir","family":"Dokmeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentius A.","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Sollano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv K.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-8890","authenticated-orcid":false,"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"10276_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u2013926","journal-title":"BMJ"},{"key":"10276_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","volume":"56","author":"K Boonstra","year":"2012","unstructured":"Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181\u20131188","journal-title":"J Hepatol"},{"key":"10276_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/jgh.15329","volume":"36","author":"T Lv","year":"2020","unstructured":"Lv T, Chen S, Li M, et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;36:1423\u20131434","journal-title":"J Gastroenterol Hepatol"},{"key":"10276_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s12072-019-09984-x","volume":"13","author":"N Zeng","year":"2019","unstructured":"Zeng N, Duan W, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia\u2013Pacific region: a systematic review and meta-analysis. Hepatol Int. 2019;13:788\u2013799","journal-title":"Hepatol Int"},{"key":"10276_CR5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12072-011-9329-0","volume":"6","author":"JH Ngu","year":"2012","unstructured":"Ngu JH, Gearry RB, Wright AJ, et al. Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: a population-based study. Hepatol Int. 2012;6:796\u2013800","journal-title":"Hepatol Int"},{"key":"10276_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1053\/j.gastro.2004.04.064","volume":"127","author":"S Sood","year":"2004","unstructured":"Sood S, Gow PJ, Christie JM, et al. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology. 2004;127:470\u2013475","journal-title":"Gastroenterology"},{"key":"10276_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S1386-6346(03)00167-0","volume":"26","author":"H Sakugawa","year":"2003","unstructured":"Sakugawa H, Nakasone H, Nakayoshi T, et al. Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa Japan. Hepatol Res. 2003;26:330\u2013336","journal-title":"Hepatol Res"},{"key":"10276_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00535-003-1285-6","volume":"39","author":"M Shibata","year":"2004","unstructured":"Shibata M, Onozuka Y, Morizane T, et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J Gastroenterol. 2004;39:255\u2013259","journal-title":"J Gastroenterol"},{"key":"10276_CR9","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.3748\/wjg.v9.i9.2128","volume":"9","author":"XH Jiang","year":"2003","unstructured":"Jiang XH, Zhong RQ, Fan XY, et al. Characterization of M2 antibodies in asymptomatic Chinese population. World J Gastroenterol. 2003;9:2128\u20132131","journal-title":"World J Gastroenterol"},{"key":"10276_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1471-230X-10-100","volume":"10","author":"H Liu","year":"2010","unstructured":"Liu H, Liu Y, Wang L, et al. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol. 2010;10:100","journal-title":"BMC Gastroenterol"},{"key":"10276_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/apt.13448","volume":"43","author":"KA Kim","year":"2016","unstructured":"Kim KA, Ki M, Choi HY, et al. Population-based epidemiology of primary biliary cirrhosis in South Korea. Aliment Pharmacol Ther. 2016;43:154\u2013162","journal-title":"Aliment Pharmacol Ther"},{"key":"10276_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/hepr.13342","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Mori M, Matsumoto K, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res. 2019;49:881\u2013889","journal-title":"Hepatol Res"},{"key":"10276_CR13","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1038\/ctg.2017.43","volume":"8","author":"KS Cheung","year":"2017","unstructured":"Cheung KS, Seto WK, Fung J, et al. Epidemiology and natural history of primary biliary cholangitis in the Chinese: a territory-based study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017;8:e116","journal-title":"Clin Transl Gastroenterol"},{"key":"10276_CR14","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1111\/j.1440-1746.2007.05048.x","volume":"22","author":"DN Amarapurkar","year":"2007","unstructured":"Amarapurkar DN, Patel ND. Spectrum of autoimmune liver diseases in western India. J Gastroenterol Hepatol. 2007;22:2112\u20132117","journal-title":"J Gastroenterol Hepatol"},{"key":"10276_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1055\/s-0039-1697617","volume":"40","author":"A Lleo","year":"2020","unstructured":"Lleo A, Leung PSC, Hirschfield GM, et al. The pathogenesis of primary biliary cholangitis: a comprehensive review. Semin Liver Dis. 2020;40:34\u201348","journal-title":"Semin Liver Dis"},{"key":"10276_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","volume":"17","author":"AF Gulamhusein","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol. 2020;17:93\u2013110","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10276_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.15403\/jgld-181","volume":"28","author":"K Wijarnpreecha","year":"2019","unstructured":"Wijarnpreecha K, Werlang M, Panjawatanan P, et al. Association between smoking and risk of primary biliary cholangitis: a systematic review and meta-analysis. J Gastrointestin Liver Dis. 2019;28:197\u2013203","journal-title":"J Gastrointestin Liver Dis"},{"key":"10276_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/hep.21076","volume":"43","author":"A Ala","year":"2006","unstructured":"Ala A, Stanca CM, Bu-Ghanim M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology. 2006;43:525\u2013531","journal-title":"Hepatology"},{"key":"10276_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/gut.2009.184218","volume":"59","author":"MI Prince","year":"2010","unstructured":"Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut. 2010;59:508\u2013512","journal-title":"Gut"},{"key":"10276_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jhep.2010.02.019","volume":"53","author":"C Corpechot","year":"2010","unstructured":"Corpechot C, Chr\u00e9tien Y, Chazouill\u00e8res O, et al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53:162\u2013169","journal-title":"J Hepatol"},{"key":"10276_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","volume":"67","author":"R Tang","year":"2018","unstructured":"Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2018;67:534\u2013541","journal-title":"Gut"},{"key":"10276_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1055\/s-0035-1567831","volume":"35","author":"AF Gulamhusein","year":"2015","unstructured":"Gulamhusein AF, Juran BD, Lazaridis KN. Genome-wide association studies in primary biliary cirrhosis. Semin Liver Dis. 2015;35:392\u2013401","journal-title":"Semin Liver Dis"},{"key":"10276_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/eji.201344270","volume":"44","author":"M Carbone","year":"2014","unstructured":"Carbone M, Lleo A, Sandford RN, et al. Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. Eur J Immunol. 2014;44:945\u2013954","journal-title":"Eur J Immunol"},{"key":"10276_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/hep.30604","volume":"70","author":"C Wang","year":"2019","unstructured":"Wang C, Zheng X, Jiang P, et al. Genome-wide association studies of specific antinuclear autoantibody subphenotypes in primary biliary cholangitis. Hepatology. 2019;70:294\u2013307","journal-title":"Hepatology"},{"key":"10276_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","volume":"8","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol. 2013;8:303\u2013330","journal-title":"Annu Rev Pathol"},{"key":"10276_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41598-018-36490-1","volume":"9","author":"Y Hitomi","year":"2019","unstructured":"Hitomi Y, Ueno K, Kawai Y, et al. POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33. Sci Rep. 2019;9:102","journal-title":"Sci Rep"},{"key":"10276_CR27","doi-asserted-by":"publisher","first-page":"14828","DOI":"10.1038\/ncomms14828","volume":"8","author":"F Qiu","year":"2017","unstructured":"Qiu F, Tang R, Zuo X, et al. A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. Nat Commun. 2017;8:14828","journal-title":"Nat Commun"},{"key":"10276_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/156652409787314525","volume":"9","author":"C Selmi","year":"2009","unstructured":"Selmi C, Lleo A, Pasini S, et al. Innate immunity and primary biliary cirrhosis. Curr Mol Med. 2009;9:45\u201351","journal-title":"Curr Mol Med"},{"key":"10276_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.gastro.2004.11.005","volume":"128","author":"K Kikuchi","year":"2005","unstructured":"Kikuchi K, Lian ZX, Yang GX, et al. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology. 2005;128:304\u2013312","journal-title":"Gastroenterology"},{"key":"10276_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.23318","volume":"51","author":"S Shimoda","year":"2010","unstructured":"Shimoda S, Harada K, Niiro H, et al. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology. 2010;51:567\u2013575","journal-title":"Hepatology"},{"key":"10276_CR31","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/hep.20859","volume":"42","author":"TK Mao","year":"2005","unstructured":"Mao TK, Lian ZX, Selmi C, et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology. 2005;42:802\u2013808","journal-title":"Hepatology"},{"key":"10276_CR32","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1053\/j.gastro.2011.02.044","volume":"140","author":"M Trauner","year":"2011","unstructured":"Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology. 2011;140:1120-1125.e1\u201312","journal-title":"Gastroenterology"},{"key":"10276_CR33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/hep.24526","volume":"54","author":"M Tsuda","year":"2011","unstructured":"Tsuda M, Ambrosini YM, Zhang W, et al. Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. Hepatology. 2011;54:1293\u20131302","journal-title":"Hepatology"},{"key":"10276_CR34","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.21123","volume":"43","author":"RY Lan","year":"2006","unstructured":"Lan RY, Cheng C, Lian ZX, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology. 2006;43:729\u2013737","journal-title":"Hepatology"},{"key":"10276_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/hep.29418","volume":"67","author":"H Zhang","year":"2018","unstructured":"Zhang H, Lian M, Zhang J, et al. A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation. Hepatology. 2018;67:232\u2013246","journal-title":"Hepatology"},{"key":"10276_CR36","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/liv.14136","volume":"39","author":"SX Li","year":"2019","unstructured":"Li SX, Lv TT, Zhang CP, et al. Alteration of liver-infiltrated and peripheral blood double-negative T cells in primary biliary cholangitis. Liver Int. 2019;39:1755\u20131767","journal-title":"Liver Int"},{"key":"10276_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jaut.2018.01.007","volume":"90","author":"X Jiang","year":"2018","unstructured":"Jiang X, Lian M, Li Y, et al. The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7. J Autoimmun. 2018;90:64\u201375","journal-title":"J Autoimmun"},{"key":"10276_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0168-8278(03)00387-8","volume":"39","author":"DS Kyriakou","year":"2003","unstructured":"Kyriakou DS, Alexandrakis MG, Zachou K, et al. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol. 2003;39:679\u2013685","journal-title":"J Hepatol"},{"key":"10276_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaut.2005.08.002","volume":"25","author":"K Zachou","year":"2005","unstructured":"Zachou K, Rigopoulou EI, Tsikrikoni A, et al. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J Autoimmun. 2005;25:283\u2013288","journal-title":"J Autoimmun"},{"key":"10276_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jhep.2004.11.023","volume":"42","author":"A Tsikrikoni","year":"2005","unstructured":"Tsikrikoni A, Kyriakou DS, Rigopoulou EI, et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol. 2005;42:393\u2013399","journal-title":"J Hepatol"},{"key":"10276_CR41","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","volume":"377","author":"C Selmi","year":"2011","unstructured":"Selmi C, Bowlus CL, Gershwin ME, et al. Primary biliary cirrhosis. Lancet. 2011;377:1600\u20131609","journal-title":"Lancet"},{"key":"10276_CR42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394\u2013419","journal-title":"Hepatology"},{"key":"10276_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"EASL Clinical Practice Guidelines","year":"2017","unstructured":"EASL Clinical Practice Guidelines. The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145\u2013172","journal-title":"J Hepatol"},{"key":"10276_CR44","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","volume":"67","author":"GM Hirschfield","year":"2018","unstructured":"Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67:1568\u20131594","journal-title":"Gut"},{"key":"10276_CR45","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/jgh.14521","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Duan W, Li M, et al. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: a single center follow-up study from China. J Gastroenterol Hepatol. 2018;34:1236\u20131241","journal-title":"J Gastroenterol Hepatol"},{"key":"10276_CR46","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1038\/s41598-019-44081-x","volume":"9","author":"CY Lin","year":"2019","unstructured":"Lin CY, Cheng YT, Chang ML, et al. The extrahepatic events of Asian patients with primary biliary cholangitis: a 30-year cohort study. Sci Rep. 2019;9:7577","journal-title":"Sci Rep"},{"key":"10276_CR47","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.29717","volume":"67","author":"PCF Murillo","year":"2018","unstructured":"Murillo PCF, Goet JC, Lammers WJ, et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history. Hepatology. 2018;67:1920\u20131930","journal-title":"Hepatology"},{"key":"10276_CR48","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1007\/s00535-009-0090-2","volume":"44","author":"J Kubota","year":"2009","unstructured":"Kubota J, Ikeda F, Terada R, et al. Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. J Gastroenterol. 2009;44:1000\u20131006","journal-title":"J Gastroenterol"},{"key":"10276_CR49","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/gut.2003.023937","volume":"53","author":"MI Prince","year":"2004","unstructured":"Prince MI, Chetwynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004;53:865\u2013870","journal-title":"Gut"},{"key":"10276_CR50","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","volume":"386","author":"EJ Carey","year":"2015","unstructured":"Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386:1565\u20131575","journal-title":"Lancet"},{"key":"10276_CR51","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2013.04.017","volume":"59","author":"M Carbone","year":"2013","unstructured":"Carbone M, Bufton S, Monaco A, et al. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol. 2013;59:490\u2013494","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10276_CR52","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","volume":"18","author":"JD Fisk","year":"1994","unstructured":"Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79-83","journal-title":"Clin Infect Dis"},{"key":"10276_CR53","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1136\/gut.2005.065862","volume":"54","author":"A Jacoby","year":"2005","unstructured":"Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54:1622\u20131629","journal-title":"Gut"},{"key":"10276_CR54","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrgastro.2010.62","volume":"7","author":"G Abbas","year":"2010","unstructured":"Abbas G, Jorgensen RA, Lindor KD. Fatigue in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol. 2010;7:313\u2013319","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10276_CR55","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291\u2013308","journal-title":"Hepatology"},{"key":"10276_CR56","doi-asserted-by":"publisher","first-page":"12542","DOI":"10.1038\/s41598-018-31063-8","volume":"8","author":"M Yagi","year":"2018","unstructured":"Yagi M, Tanaka A, Abe M, et al. Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis. Sci Rep. 2018;8:12542","journal-title":"Sci Rep"},{"key":"10276_CR57","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/flgastro-2015-100618","volume":"7","author":"VS Hegade","year":"2016","unstructured":"Hegade VS, Bolier R, Oude ERP, et al. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Front Gastroenterol. 2016;7:158\u2013166","journal-title":"Front Gastroenterol"},{"key":"10276_CR58","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5009\/gnl16365","volume":"11","author":"SL Chalifoux","year":"2017","unstructured":"Chalifoux SL, Konyn PG, Choi G, et al. Extrahepatic manifestations of primary biliary cholangitis. Gut Liver. 2017;11:771\u2013780","journal-title":"Gut Liver"},{"key":"10276_CR59","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","volume":"48","author":"A Floreani","year":"2015","unstructured":"Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48:192\u2013197","journal-title":"Clin Rev Allergy Immunol"},{"key":"10276_CR60","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/jgh.15214","volume":"36","author":"C Efe","year":"2021","unstructured":"Efe C, Torgutalp M, Henriksson I, et al. Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence and significance for clinical presentation and disease outcome. J Gastroenterol Hepatol. 2021;36:936\u2013942","journal-title":"J Gastroenterol Hepatol"},{"key":"10276_CR61","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2036.2007.03433.x","volume":"26","author":"A Granito","year":"2007","unstructured":"Granito A, Muratori P, Muratori L, et al. Antibodies to SS-A\/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;26:831\u2013838","journal-title":"Aliment Pharmacol Ther"},{"key":"10276_CR62","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1440-1746.1995.tb01597.x","volume":"10","author":"S Parveen","year":"1995","unstructured":"Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol. 1995;10:438\u2013445","journal-title":"J Gastroenterol Hepatol"},{"key":"10276_CR63","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1136\/gut.2005.079814","volume":"55","author":"M Allocca","year":"2006","unstructured":"Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. 2006;55:1795\u20131800","journal-title":"Gut"},{"key":"10276_CR64","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s10067-017-3844-x","volume":"36","author":"J Fan","year":"2017","unstructured":"Fan J, Wang Q, Sun L. Association between primary biliary cholangitis and osteoporosis: meta-analysis. Clin Rheumatol. 2017;36:2565\u20132571","journal-title":"Clin Rheumatol"},{"key":"10276_CR65","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1089-3261(03)00097-7","volume":"7","author":"C Levy","year":"2003","unstructured":"Levy C, Lindor KD. Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis. 2003;7:901\u2013910","journal-title":"Clin Liver Dis"},{"key":"10276_CR66","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/0016-5085(92)90771-P","volume":"102","author":"F Colina","year":"1992","unstructured":"Colina F, Pinedo F, Sol\u00eds JA, et al. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology. 1992;102:1319\u20131324","journal-title":"Gastroenterology"},{"key":"10276_CR67","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12016-015-8483-x","volume":"48","author":"G Rong","year":"2015","unstructured":"Rong G, Wang H, Bowlus CL, et al. Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48:132\u2013141","journal-title":"Clin Rev Allergy Immunol"},{"key":"10276_CR68","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/hep.26176","volume":"57","author":"K Harada","year":"2013","unstructured":"Harada K, Hirohara J, Ueno Y, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology. 2013;57:1942\u20131949","journal-title":"Hepatology"},{"key":"10276_CR69","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/cancers13051023","volume":"13","author":"EI Rigopoulou","year":"2021","unstructured":"Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel). 2021;13:1023","journal-title":"Cancers (Basel)"},{"key":"10276_CR70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1586\/erm.11.82","volume":"12","author":"A Granito","year":"2012","unstructured":"Granito A, Muratori P, Quarneti C, et al. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn. 2012;12:65\u201374","journal-title":"Expert Rev Mol Diagn"},{"key":"10276_CR71","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14737159.2016.1217159","volume":"16","author":"NK Gatselis","year":"2016","unstructured":"Gatselis NK, Dalekos GN. Molecular diagnostic testing for primary biliary cholangitis. Expert Rev Mol Diagn. 2016;16:1001\u20131010","journal-title":"Expert Rev Mol Diagn"},{"key":"10276_CR72","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/liv.12732","volume":"35","author":"D Vergani","year":"2015","unstructured":"Vergani D. Towards the serological diagnosis of primary biliary cirrhosis. Liver Int. 2015;35:299\u2013301","journal-title":"Liver Int"},{"key":"10276_CR73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00005-019-00550-9","volume":"67","author":"GN Dalekos","year":"2019","unstructured":"Dalekos GN, Gatselis NK. Variant and specific forms of autoimmune cholestatic liver diseases. Arch Immunol Ther Exp (Warsz). 2019;67:197\u2013211","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10276_CR74","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s10875-007-9092-0","volume":"27","author":"S Gabeta","year":"2007","unstructured":"Gabeta S, Norman GL, Liaskos C, et al. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol. 2007;27:378\u201387.","journal-title":"J Clin Immunol"},{"key":"10276_CR75","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jaut.2010.09.005","volume":"35","author":"H Liu","year":"2010","unstructured":"Liu H, Norman GL, Shums Z, et al. PBC screen: an IgG\/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35:436\u201342.","journal-title":"J Autoimmun"},{"key":"10276_CR76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.dld.2004.09.019","volume":"37","author":"L Muratori","year":"2005","unstructured":"Muratori L, Muratori P, Granito A, et al. The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis. Dig Liver Dis. 2005;37:108\u2013112","journal-title":"Dig Liver Dis"},{"key":"10276_CR77","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/hep.21828","volume":"46","author":"PS Leung","year":"2007","unstructured":"Leung PS, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology. 2007;46:1436\u20131442","journal-title":"Hepatology"},{"key":"10276_CR78","doi-asserted-by":"publisher","first-page":"8959103","DOI":"10.1155\/2019\/8959103","volume":"2019","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Liu Z, Wu S, et al. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Gastroenterol Res Pract. 2019;2019:8959103","journal-title":"Gastroenterol Res Pract"},{"key":"10276_CR79","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/j.1365-2036.2006.03172.x","volume":"24","author":"A Granito","year":"2006","unstructured":"Granito A, Muratori P, Muratori L, et al. Antinuclear antibodies giving the \u201cmultiple nuclear dots\u201d or the \u201crim-like\/membranous\u201d patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24:1575\u20131583","journal-title":"Aliment Pharmacol Ther"},{"key":"10276_CR80","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/liv.12690","volume":"35","author":"GL Norman","year":"2015","unstructured":"Norman GL, Yang CY, Ostendorff HP, et al. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int. 2015;35:642\u2013651","journal-title":"Liver Int"},{"key":"10276_CR81","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/hep.20619","volume":"41","author":"C Janka","year":"2005","unstructured":"Janka C, Selmi C, Gershwin ME, et al. Small ubiquitin-related modifiers: a novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology. 2005;41:609\u2013616","journal-title":"Hepatology"},{"key":"10276_CR82","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ajg.2009.596","volume":"105","author":"A Granito","year":"2010","unstructured":"Granito A, Yang WH, Muratori L, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:125\u2013131","journal-title":"Am J Gastroenterol"},{"key":"10276_CR83","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1586\/1744666X.2014.979792","volume":"10","author":"AH Ali","year":"2014","unstructured":"Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis. Expert Rev Clin Immunol. 2014;10:1667\u20131678","journal-title":"Expert Rev Clin Immunol"},{"key":"10276_CR84","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.21472","volume":"45","author":"M Nakamura","year":"2007","unstructured":"Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118\u2013127","journal-title":"Hepatology"},{"key":"10276_CR85","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ejrad.2007.11.003","volume":"69","author":"N Haliloglu","year":"2009","unstructured":"Haliloglu N, Erden A, Erden I. Primary biliary cirrhosis: evaluation with T2-weighted MR imaging and MR cholangiopancreatography. Eur J Radiol. 2009;69:523\u2013527","journal-title":"Eur J Radiol"},{"key":"10276_CR86","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.25599","volume":"56","author":"C Corpechot","year":"2012","unstructured":"Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56:198\u2013208","journal-title":"Hepatology"},{"key":"10276_CR87","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/MCG.0b013e3181a84b8d","volume":"44","author":"M Friedrich-Rust","year":"2010","unstructured":"Friedrich-Rust M, M\u00fcller C, Winckler A, et al. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. J Clin Gastroenterol. 2010;44:58\u201365","journal-title":"J Clin Gastroenterol"},{"key":"10276_CR88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00432479","volume":"379","author":"J Ludwig","year":"1978","unstructured":"Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103\u2013112","journal-title":"Virchows Arch A Pathol Anat Histol"},{"issue":"Suppl 4","key":"10276_CR89","first-page":"106","volume":"59","author":"PJ Scheuer","year":"1983","unstructured":"Scheuer PJ. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med J. 1983;59(Suppl 4):106\u2013115","journal-title":"Postgrad Med J"},{"key":"10276_CR90","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/hep.510290444","volume":"29","author":"C Degott","year":"1999","unstructured":"Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology. 1999;29:1007\u20131012","journal-title":"Hepatology"},{"key":"10276_CR91","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/gast.2002.31880","volume":"122","author":"C Corpechot","year":"2002","unstructured":"Corpechot C, Carrat F, Poupon R, et al. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology. 2002;122:652\u2013658","journal-title":"Gastroenterology"},{"key":"10276_CR92","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","volume":"60","author":"Y Nakanuma","year":"2010","unstructured":"Nakanuma Y, Zen Y, Harada K, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int. 2010;60:167\u2013174","journal-title":"Pathol Int"},{"key":"10276_CR93","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MCG.0b013e31827234e4","volume":"47","author":"K Harada","year":"2013","unstructured":"Harada K, Hsu M, Ikeda H, et al. Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol. 2013;47:174\u2013181","journal-title":"J Clin Gastroenterol"},{"key":"10276_CR94","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.humpath.2012.09.017","volume":"44","author":"Y Kakuda","year":"2013","unstructured":"Kakuda Y, Harada K, Sawada-Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol. 2013;44:1107\u20131117","journal-title":"Hum Pathol"},{"key":"10276_CR95","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2478\/jtim-2021-0008","volume":"9","author":"PA Papamichalis","year":"2021","unstructured":"Papamichalis PA, Zachou K, Papamichali RA, et al. Promyelocytic leukemia antigen expression: a histological marker for primary biliary cholangitis diagnosis. J Transl Int Med. 2021;9:43\u201351","journal-title":"J Transl Int Med"},{"key":"10276_CR96","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jhep.2011.03.031","volume":"56","author":"C Corpechot","year":"2012","unstructured":"Corpechot C, Gaouar F, Chr\u00e9tien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol. 2012;56:218\u2013224","journal-title":"J Hepatol"},{"key":"10276_CR97","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/MCG.0b013e318261e659","volume":"47","author":"M H\u00edndi","year":"2013","unstructured":"H\u00edndi M, Levy C, Couto CA, et al. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol. 2013;47:e28-32","journal-title":"J Clin Gastroenterol"},{"key":"10276_CR98","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/liv.13644","volume":"38","author":"GY Minuk","year":"2018","unstructured":"Minuk GY, Iliant V, Zhou N, et al. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. Liver Int. 2018;38:1110\u20131116","journal-title":"Liver Int"},{"key":"10276_CR99","unstructured":"Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis). Zhonghua Gan Zang Bing Za Zhi 2016;24:5\u201313."},{"key":"10276_CR100","doi-asserted-by":"crossref","unstructured":"Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res 2014;44 (Suppl S1):71\u201390.","DOI":"10.1111\/hepr.12270"},{"key":"10276_CR101","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","volume":"30","author":"P Angulo","year":"1999","unstructured":"Angulo P, Dickson ER, Therneau TM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol. 1999;30:830\u2013835","journal-title":"J Hepatol"},{"key":"10276_CR102","doi-asserted-by":"publisher","first-page":"e5391","DOI":"10.1097\/MD.0000000000005391","volume":"95","author":"H Ma","year":"2016","unstructured":"Ma H, Zeng M, Han Y, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore). 2016;95:e5391","journal-title":"Medicine (Baltimore)"},{"key":"10276_CR103","first-page":"CD000551","volume":"12","author":"JS Rudic","year":"2012","unstructured":"Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551","journal-title":"Cochrane Database Syst Rev"},{"key":"10276_CR104","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","volume":"102","author":"Y Gong","year":"2007","unstructured":"Gong Y, Huang Z, Christensen E, et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007;102:1799\u20131807","journal-title":"Am J Gastroenterol"},{"key":"10276_CR105","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","volume":"101","author":"J Shi","year":"2006","unstructured":"Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101:1529\u20131538","journal-title":"Am J Gastroenterol"},{"key":"10276_CR106","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","volume":"39","author":"RE Poupon","year":"2003","unstructured":"Poupon RE, Lindor KD, Par\u00e9s A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol. 2003;39:12\u201316","journal-title":"J Hepatol"},{"key":"10276_CR107","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/hep.510290301","volume":"29","author":"P Angulo","year":"1999","unstructured":"Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999;29:644\u2013647","journal-title":"Hepatology"},{"key":"10276_CR108","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","volume":"128","author":"C Corpechot","year":"2005","unstructured":"Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297\u2013303","journal-title":"Gastroenterology"},{"key":"10276_CR109","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71:357\u2013365","journal-title":"J Hepatol"},{"key":"10276_CR110","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.clinre.2018.08.006","volume":"43","author":"MC Leoni","year":"2019","unstructured":"Leoni MC, Amelung L, Lieveld FI, et al. Adherence to ursodeoxycholic acid therapy in patients with cholestatic and autoimmune liver disease. Clin Res Hepatol Gastroenterol. 2019;43:37\u201344","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10276_CR111","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871\u2013877","journal-title":"Hepatology"},{"key":"10276_CR112","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","volume":"144","author":"M Carbone","year":"2013","unstructured":"Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144:560-569.e7 (quiz e13\u201314)","journal-title":"Gastroenterology"},{"key":"10276_CR113","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cgh.2019.08.013","volume":"18","author":"NK Gatselis","year":"2020","unstructured":"Gatselis NK, Goet JC, Zachou K, et al. Factors associated with progression and outcomes of early stage primary biliary cholangitis. Clin Gastroenterol Hepatol. 2020;18:684-692.e6","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10276_CR114","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/hep.26322","volume":"58","author":"LN Zhang","year":"2013","unstructured":"Zhang LN, Shi TY, Shi XH, et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology. 2013;58:264\u2013272","journal-title":"Hepatology"},{"key":"10276_CR115","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006;130:715\u2013720","journal-title":"Gastroenterology"},{"key":"10276_CR116","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","volume":"19","author":"P Angulo","year":"1999","unstructured":"Angulo P, Lindor KD, Therneau TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;19:115\u2013121","journal-title":"Liver"},{"key":"10276_CR117","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EM Kuiper","year":"2009","unstructured":"Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281\u20131287","journal-title":"Gastroenterology"},{"key":"10276_CR118","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","volume":"44","author":"N Azemoto","year":"2009","unstructured":"Azemoto N, Abe M, Murata Y, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol. 2009;44:630\u2013634","journal-title":"J Gastroenterol"},{"key":"10276_CR119","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186\u20132194","journal-title":"Am J Gastroenterol"},{"key":"10276_CR120","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","volume":"32","author":"N Momah","year":"2012","unstructured":"Momah N, Silveira MG, Jorgensen R, et al. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 2012;32:790\u2013795","journal-title":"Liver Int"},{"key":"10276_CR121","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot C, Chazouill\u00e8res O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361\u20131367","journal-title":"J Hepatol"},{"key":"10276_CR122","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s12072-017-9819-9","volume":"11","author":"S Chen","year":"2017","unstructured":"Chen S, Duan W, You H, et al. A brief review on prognostic models of primary biliary cholangitis. Hepatol Int. 2017;11:412\u2013418","journal-title":"Hepatol Int"},{"key":"10276_CR123","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","volume":"149","author":"WJ Lammers","year":"2015","unstructured":"Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149:1804-1812.e4","journal-title":"Gastroenterology"},{"key":"10276_CR124","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/hep.28017","volume":"63","author":"M Carbone","year":"2016","unstructured":"Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63:930\u2013950","journal-title":"Hepatology"},{"key":"10276_CR125","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.14309\/ajg.0000000000000290","volume":"114","author":"C Efe","year":"2019","unstructured":"Efe C, Ta\u015f\u00e7ilar K, Henriksson I, et al. Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis. Am J Gastroenterol. 2019;114:1101\u20131108","journal-title":"Am J Gastroenterol"},{"key":"10276_CR126","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","volume":"147","author":"WJ Lammers","year":"2014","unstructured":"Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147:1338-1349.e5 (quiz e15)","journal-title":"Gastroenterology"},{"key":"10276_CR127","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","volume":"115","author":"PCF Murillo","year":"2020","unstructured":"Murillo PCF, Harms MH, Lindor KD, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115:1066\u20131074","journal-title":"Am J Gastroenterol"},{"key":"10276_CR128","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","volume":"3","author":"M Carbone","year":"2018","unstructured":"Carbone M, Nardi A, Flack S, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol. 2018;3:626\u2013634","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10276_CR129","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/liv.14534","volume":"40","author":"M Yagi","year":"2020","unstructured":"Yagi M, Matsumoto K, Komori A, et al. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. Liver Int. 2020;40:1926\u20131933","journal-title":"Liver Int"},{"key":"10276_CR130","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751-761.e8","journal-title":"Gastroenterology"},{"key":"10276_CR131","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","volume":"67","author":"KV Kowdley","year":"2018","unstructured":"Kowdley KV, Luketic V, Chapman R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018;67:1890\u20131902","journal-title":"Hepatology"},{"key":"10276_CR132","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al. A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631\u2013643","journal-title":"N Engl J Med"},{"key":"10276_CR133","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","volume":"4","author":"M Trauner","year":"2019","unstructured":"Trauner M, Nevens F, Shiffman ML, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4:445\u2013453","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10276_CR134","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","volume":"13","author":"XF Han","year":"2012","unstructured":"Han XF, Wang QX, Liu Y, et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis. 2012;13:219\u2013224","journal-title":"J Dig Dis"},{"key":"10276_CR135","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","volume":"97","author":"H Ohira","year":"2002","unstructured":"Ohira H, Sato Y, Ueno T, et al. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol. 2002;97:2147\u20132149","journal-title":"Am J Gastroenterol"},{"key":"10276_CR136","first-page":"2757","volume":"9","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Li S, He L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Drug Des Devel Ther. 2015;9:2757\u20132766","journal-title":"Drug Des Devel Ther"},{"key":"10276_CR137","doi-asserted-by":"publisher","first-page":"557","DOI":"10.17235\/reed.2018.5533\/2018","volume":"110","author":"W Duan","year":"2018","unstructured":"Duan W, Ou X, Wang X, et al. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. Rev Esp Enferm Dig. 2018;110:557\u2013563","journal-title":"Rev Esp Enferm Dig"},{"key":"10276_CR138","first-page":"5407","volume":"9","author":"Q Yin","year":"2015","unstructured":"Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des Devel Ther. 2015;9:5407\u201319.","journal-title":"Drug Des Devel Ther"},{"key":"10276_CR139","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ajg.2017.287","volume":"113","author":"A Reig","year":"2018","unstructured":"Reig A, Ses\u00e9 P, Par\u00e9s A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol. 2018;113:49\u201355","journal-title":"Am J Gastroenterol"},{"key":"10276_CR140","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171\u20132181","journal-title":"N Engl J Med"},{"key":"10276_CR141","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/hep.30552","volume":"70","author":"A Honda","year":"2019","unstructured":"Honda A, Tanaka A, Kaneko T, et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology. 2019;70:2035\u20132046","journal-title":"Hepatology"},{"key":"10276_CR142","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","volume":"160","author":"E de Vries","year":"2021","unstructured":"de Vries E, Bolier R, Goet J, et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized placebo-controlled Trial. Gastroenterology. 2021;160:734-743.e6","journal-title":"Gastroenterology"},{"key":"10276_CR143","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13063-017-1966-8","volume":"18","author":"R Bolier","year":"2017","unstructured":"Bolier R, de Vries ES, Par\u00e9s A, et al. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials. 2017;18:230","journal-title":"Trials"},{"key":"10276_CR144","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/hep.20646","volume":"41","author":"H Rautiainen","year":"2005","unstructured":"Rautiainen H, K\u00e4rkk\u00e4inen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology. 2005;41:747\u2013752","journal-title":"Hepatology"},{"key":"10276_CR145","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","volume":"117","author":"M Leuschner","year":"1999","unstructured":"Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999;117:918\u2013925","journal-title":"Gastroenterology"},{"key":"10276_CR146","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","volume":"74","author":"GM Hirschfield","year":"2021","unstructured":"Hirschfield GM, Beuers U, Kupcinskas L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2021;74:321\u2013329","journal-title":"J Hepatol"},{"key":"10276_CR147","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/jhep.2003.50266","volume":"38","author":"W Hempfling","year":"2003","unstructured":"Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003;38:196\u2013202","journal-title":"Hepatology"},{"key":"10276_CR148","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","volume":"60","author":"U Beuers","year":"2014","unstructured":"Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60:399\u2013407","journal-title":"Hepatology"},{"key":"10276_CR149","doi-asserted-by":"publisher","first-page":"48431","DOI":"10.7554\/eLife.48431","volume":"8","author":"H Yu","year":"2019","unstructured":"Yu H, Zhao T, Liu S, et al. MRGPRX4 is a bile acid receptor for human cholestatic itch. Elife. 2019;8:48431","journal-title":"Elife"},{"key":"10276_CR150","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0016-5085(66)80071-9","volume":"50","author":"DV Datta","year":"1966","unstructured":"Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50:323\u2013332","journal-title":"Gastroenterology"},{"key":"10276_CR151","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","volume":"102","author":"P Tandon","year":"2007","unstructured":"Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007;102:1528\u20131536","journal-title":"Am J Gastroenterol"},{"key":"10276_CR152","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","volume":"26","author":"S Khurana","year":"2006","unstructured":"Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26:943\u2013948","journal-title":"Liver Int"},{"key":"10276_CR153","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","volume":"1","author":"L Bachs","year":"1989","unstructured":"Bachs L, Par\u00e9s A, Elena M, et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989;1:574\u2013576","journal-title":"Lancet"},{"key":"10276_CR154","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/gut.50.3.436","volume":"50","author":"MI Prince","year":"2002","unstructured":"Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436\u2013439","journal-title":"Gut"},{"key":"10276_CR155","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00004714-200002000-00023","volume":"20","author":"JS Markowitz","year":"2000","unstructured":"Markowitz JS, DeVane CL. Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. J Clin Psychopharmacol. 2000;20:109\u2013110","journal-title":"J Clin Psychopharmacol"},{"key":"10276_CR156","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00535-018-1465-z","volume":"53","author":"M Yagi","year":"2018","unstructured":"Yagi M, Tanaka A, Namisaki T, et al. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol. 2018;53:1151\u20131158","journal-title":"J Gastroenterol"},{"key":"10276_CR157","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","volume":"389","author":"VS Hegade","year":"2017","unstructured":"Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389:1114\u20131123","journal-title":"Lancet"},{"key":"10276_CR158","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","volume":"135","author":"EH Buster","year":"2008","unstructured":"Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459\u2013467","journal-title":"Gastroenterology"},{"key":"10276_CR159","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019;70:172\u2013193.","DOI":"10.1016\/j.jhep.2018.06.024"},{"key":"10276_CR160","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/apt.13244","volume":"42","author":"GY Guo","year":"2015","unstructured":"Guo GY, Shi YQ, Wang L, et al. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. Aliment Pharmacol Ther. 2015;42:221\u2013230","journal-title":"Aliment Pharmacol Ther"},{"key":"10276_CR161","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12026-014-8594-0","volume":"61","author":"N Agmon-Levin","year":"2015","unstructured":"Agmon-Levin N, Kopilov R, Selmi C, et al. Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease. Immunol Res. 2015;61:141\u2013146","journal-title":"Immunol Res"},{"key":"10276_CR162","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/00365521.2020.1829030","volume":"55","author":"Z Wang","year":"2020","unstructured":"Wang Z, Peng C, Wang P, et al. Serum vitamin D level is related to disease progression in primary biliary cholangitis. Scand J Gastroenterol. 2020;55:1333\u20131340","journal-title":"Scand J Gastroenterol"},{"key":"10276_CR163","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","volume":"138","author":"N Gua\u00f1abens","year":"2010","unstructured":"Gua\u00f1abens N, Cerd\u00e1 D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology. 2010;138:2348\u20132356","journal-title":"Gastroenterology"},{"key":"10276_CR164","doi-asserted-by":"crossref","unstructured":"Rudic JS, Giljaca V, Krstic MN, et al. Bisphosphonates for osteoporosis in primary biliary cirrhosis. Cochrane Database Syst Rev 2011;CD009144.","DOI":"10.1002\/14651858.CD009144"},{"key":"10276_CR165","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1002\/hep.26466","volume":"58","author":"N Gua\u00f1abens","year":"2013","unstructured":"Gua\u00f1abens N, Monegal A, Cerd\u00e1 D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013;58:2070\u20132078","journal-title":"Hepatology"},{"key":"10276_CR166","doi-asserted-by":"crossref","unstructured":"Rudic JS, Poropat G, Krstic MN et al. Hormone replacement for osteoporosis in women with primary biliary cirrhosis. Cochrane Database Syst Rev 2011;CD009146.","DOI":"10.1002\/14651858.CD009146"},{"key":"10276_CR167","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/hep.30904","volume":"71","author":"Y Arase","year":"2019","unstructured":"Arase Y, Tsuruya K, Hirose S, et al. Efficacy and safety of 3-year denosumab therapy for osteoporosis in patients with autoimmune liver diseases. Hepatology. 2019;71:757\u2013759","journal-title":"Hepatology"},{"key":"10276_CR168","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2036.2006.03223.x","volume":"25","author":"DE Jones","year":"2007","unstructured":"Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther. 2007;25:471\u2013476","journal-title":"Aliment Pharmacol Ther"},{"key":"10276_CR169","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S1665-2681(19)30838-5","volume":"13","author":"WJ Lammers","year":"2014","unstructured":"Lammers WJ, Kowdley KV, van Buuren HR. Predicting outcome in primary biliary cirrhosis. Ann Hepatol. 2014;13:316\u2013326","journal-title":"Ann Hepatol"},{"key":"10276_CR170","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41395-018-0265-7","volume":"114","author":"C Moctezuma-Velazquez","year":"2019","unstructured":"Moctezuma-Velazquez C, Saffioti F, Tasayco-Huaman S, et al. Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol. 2019;114:446\u2013452","journal-title":"Am J Gastroenterol"},{"key":"10276_CR171","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/hep.23095","volume":"50","author":"A Cavazza","year":"2009","unstructured":"Cavazza A, Caballer\u00eda L, Floreani A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology. 2009;50:1162\u20131168","journal-title":"Hepatology"},{"key":"10276_CR172","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","volume":"65","author":"PJ Trivedi","year":"2016","unstructured":"Trivedi PJ, Lammers WJ, van Buuren HR, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;65:321\u2013329","journal-title":"Gut"},{"key":"10276_CR173","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/hepr.12242","volume":"44","author":"K Harada","year":"2014","unstructured":"Harada K, Nakanuma Y. Prevalence and risk factors of hepatocellular carcinoma in Japanese patients with primary biliary cirrhosis. Hepatol Res. 2014;44:133\u2013140","journal-title":"Hepatol Res"},{"key":"10276_CR174","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s10620-020-06498-7","volume":"66","author":"Y Natarajan","year":"2020","unstructured":"Natarajan Y, Tansel A, Patel P, et al. Incidence of hepatocellular carcinoma in primary biliary cholangitis: a systematic review and meta-analysis. Dig Dis Sci. 2020;66:2439\u20132451","journal-title":"Dig Dis Sci"},{"key":"10276_CR175","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cld.2018.03.011","volume":"22","author":"MT Aguilar","year":"2018","unstructured":"Aguilar MT, Carey EJ. Current status of liver transplantation for primary biliary cholangitis. Clin Liver Dis. 2018;22:613\u2013624","journal-title":"Clin Liver Dis"},{"key":"10276_CR176","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/hep.26972","volume":"59","author":"P Martin","year":"2014","unstructured":"Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144\u20131165","journal-title":"Hepatology"},{"key":"10276_CR177","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","volume":"57","author":"R Adam","year":"2012","unstructured":"Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57:675\u2013688","journal-title":"J Hepatol"},{"key":"10276_CR178","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jhep.2013.09.020","volume":"60","author":"M Carbone","year":"2014","unstructured":"Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014;60:210\u2013223","journal-title":"J Hepatol"},{"key":"10276_CR179","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","volume":"95","author":"AK Singal","year":"2013","unstructured":"Singal AK, Guturu P, Hmoud B, et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95:755\u2013760","journal-title":"Transplantation"},{"key":"10276_CR180","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2018.10.001","volume":"156","author":"AJ Montano-Loza","year":"2019","unstructured":"Montano-Loza AJ, Hansen BE, Corpechot C, et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology. 2019;156:96-107.e1","journal-title":"Gastroenterology"},{"key":"10276_CR181","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/jlts.2003.36392","volume":"9","author":"U Khettry","year":"2003","unstructured":"Khettry U, Anand N, Faul PN, et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl. 2003;9:87\u201396","journal-title":"Liver Transpl"},{"key":"10276_CR182","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1600-6143.2010.03038.x","volume":"10","author":"MG Silveira","year":"2010","unstructured":"Silveira MG, Talwalkar JA, Lindor KD, et al. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2010;10:720\u2013726","journal-title":"Am J Transplant"},{"key":"10276_CR183","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","volume":"63","author":"A Bosch","year":"2015","unstructured":"Bosch A, Dumortier J, Maucort-Boulch D, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J Hepatol. 2015;63:1449\u20131458","journal-title":"J Hepatol"},{"key":"10276_CR184","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","volume":"54","author":"KM Boberg","year":"2011","unstructured":"Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374\u2013385","journal-title":"J Hepatol"},{"key":"10276_CR185","doi-asserted-by":"crossref","unstructured":"Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015). J Dig Dis 2017;18:247\u2013264.","DOI":"10.1111\/1751-2980.12479"},{"key":"10276_CR186","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/apt.15111","volume":"49","author":"JK Dyson","year":"2019","unstructured":"Dyson JK, De Martin E, Dalekos GN, et al. Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Aliment Pharmacol Ther. 2019;49:528\u2013536","journal-title":"Aliment Pharmacol Ther"},{"key":"10276_CR187","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.510280203","volume":"28","author":"O Chazouill\u00e8res","year":"1998","unstructured":"Chazouill\u00e8res O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296\u2013301","journal-title":"Hepatology"},{"key":"10276_CR188","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/jgh.12952","volume":"30","author":"F Yang","year":"2015","unstructured":"Yang F, Wang Q, Bian Z, et al. Autoimmune hepatitis: east meets west. J Gastroenterol Hepatol. 2015;30:1230\u20131236","journal-title":"J Gastroenterol Hepatol"},{"key":"10276_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102328","volume":"105","author":"BB Terziroli","year":"2019","unstructured":"Terziroli BB, Mieli-Vergani G, Vergani D, et al. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun. 2019;105:","journal-title":"J Autoimmun"},{"key":"10276_CR190","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaut.2012.10.004","volume":"41","author":"Q Wang","year":"2013","unstructured":"Wang Q, Selmi C, Zhou X, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun. 2013;41:140\u2013145","journal-title":"J Autoimmun"},{"key":"10276_CR191","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/ajg.2009.126","volume":"104","author":"P Muratori","year":"2009","unstructured":"Muratori P, Granito A, Pappas G, et al. The serological profile of the autoimmune hepatitis\/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2009;104:1420\u20131425","journal-title":"Am J Gastroenterol"},{"key":"10276_CR192","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ajg.2009.602","volume":"105","author":"C Efe","year":"2010","unstructured":"Efe C, Purnak T, Ozaslan E, et al. The serological profile of the autoimmune hepatitis\/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol. 2010;105:226 (author reply 226\u2013227)","journal-title":"Am J Gastroenterol"},{"key":"10276_CR193","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cgh.2010.03.004","volume":"8","author":"EM Kuiper","year":"2010","unstructured":"Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2010;8:530\u2013534","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10276_CR194","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169\u2013176","journal-title":"Hepatology"},{"key":"10276_CR195","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929\u2013938","journal-title":"J Hepatol"},{"key":"10276_CR196","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","volume":"50","author":"F Yang","year":"2016","unstructured":"Yang F, Wang Q, Wang Z, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol. 2016;50:114\u2013123","journal-title":"Clin Rev Allergy Immunol"},{"key":"10276_CR197","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1872-034X.2011.00844.x","volume":"41","author":"A Tanaka","year":"2011","unstructured":"Tanaka A, Harada K, Ebinuma H, et al. Primary biliary cirrhosis\u2014autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res. 2011;41:877\u2013886","journal-title":"Hepatol Res"},{"key":"10276_CR198","first-page":"148","volume":"10","author":"H Zhang","year":"2015","unstructured":"Zhang H, Li S, Yang J, et al. A meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBC-AIH-overlap syndrome: evidence from 97 monotherapy and 117 combinations. Prz Gastroenterol. 2015;10:148\u2013155","journal-title":"Prz Gastroenterol"},{"key":"10276_CR199","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","volume":"12","author":"E Ozaslan","year":"2014","unstructured":"Ozaslan E, Efe C, Heurgu\u00e9-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2014;12:863\u2013869","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10276_CR200","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.cld.2008.02.003","volume":"12","author":"GM Hirschfield","year":"2008","unstructured":"Hirschfield GM, Heathcote EJ. Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis. 2008;12:323\u2013331 (viii\u2013ix)","journal-title":"Clin Liver Dis"},{"key":"10276_CR201","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/hep.510250507","volume":"25","author":"P Invernizzi","year":"1997","unstructured":"Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology. 1997;25:1090\u20131095","journal-title":"Hepatology"},{"key":"10276_CR202","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/hep.25511","volume":"55","author":"Q Jin","year":"2012","unstructured":"Jin Q, Moritoki Y, Lleo A, et al. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology. 2012;55:1495\u20131506","journal-title":"Hepatology"},{"key":"10276_CR203","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3109\/00365521.2015.1132337","volume":"51","author":"G Juliusson","year":"2016","unstructured":"Juliusson G, Imam M, Bj\u00f6rnsson ES, et al. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745\u2013752","journal-title":"Scand J Gastroenterol"},{"key":"10276_CR204","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(96)04410-8","volume":"348","author":"JV Metcalf","year":"1996","unstructured":"Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet. 1996;348:1399\u20131402","journal-title":"Lancet"},{"key":"10276_CR205","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/hep.28859","volume":"65","author":"G Dahlqvist","year":"2017","unstructured":"Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology. 2017;65:152\u2013163","journal-title":"Hepatology"},{"key":"10276_CR206","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/liv.13143","volume":"36","author":"AF Gulamhusein","year":"2016","unstructured":"Gulamhusein AF, Juran BD, Atkinson EJ, et al. Low incidence of primary biliary cirrhosis (PBC) in the first-degree relatives of PBC probands after 8 years of follow-up. Liver Int. 2016;36:1378\u20131382","journal-title":"Liver Int"},{"key":"10276_CR207","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/hep.510270303","volume":"27","author":"A Mattalia","year":"1998","unstructured":"Mattalia A, Quaranta S, Leung PS, et al. Characterization of antimitochondrial antibodies in health adults. Hepatology. 1998;27:656\u2013661","journal-title":"Hepatology"},{"key":"10276_CR208","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0895-4356(00)00370-X","volume":"54","author":"K Ohba","year":"2001","unstructured":"Ohba K, Omagari K, Kinoshita H, et al. Primary biliary cirrhosis among atomic bomb survivors in Nagasaki Japan. J Clin Epidemiol. 2001;54:845\u2013850","journal-title":"J Clin Epidemiol"},{"key":"10276_CR209","first-page":"2052","volume":"20","author":"BH Chen","year":"2016","unstructured":"Chen BH, Wang QQ, Zhang W, et al. Screening of anti-mitochondrial antibody subtype M2 in residents at least 18 years of age in an urban district of Shanghai China. Eur Rev Med Pharmacol Sci. 2016;20:2052\u20132060","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10276_CR210","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaut.2019.01.005","volume":"99","author":"C Sun","year":"2019","unstructured":"Sun C, Xiao X, Yan L, et al. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker. J Autoimmun. 2019;99:33\u201338","journal-title":"J Autoimmun"},{"key":"10276_CR211","doi-asserted-by":"publisher","first-page":"102578","DOI":"10.1016\/j.jaut.2020.102578","volume":"116","author":"BB Terziroli","year":"2021","unstructured":"Terziroli BB, Stirnimann G, Mertens J, et al. Primary biliary cholangitis with normal alkaline phosphatase: a neglected clinical entity challenging current guidelines. J Autoimmun. 2021;116:102578","journal-title":"J Autoimmun"},{"key":"10276_CR212","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jhep.2004.08.029","volume":"42","author":"R Poupon","year":"2005","unstructured":"Poupon R, Chr\u00e9tien Y, Chazouill\u00e8res O, et al. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol. 2005;42:418\u2013419","journal-title":"J Hepatol"},{"key":"10276_CR213","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2014.05.008","volume":"13","author":"C Efe","year":"2014","unstructured":"Efe C, Kahramano\u011flu-Aksoy E, Yilmaz B, et al. Pregnancy in women with primary biliary cirrhosis. Autoimmun Rev. 2014;13:931\u2013935","journal-title":"Autoimmun Rev"},{"key":"10276_CR214","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12016-014-8433-z","volume":"48","author":"A Floreani","year":"2015","unstructured":"Floreani A, Infantolino C, Franceschet I, et al. Pregnancy and primary biliary cirrhosis: a case\u2013control study. Clin Rev Allergy Immunol. 2015;48:236\u2013242","journal-title":"Clin Rev Allergy Immunol"},{"key":"10276_CR215","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(19)31270-X","volume":"394","author":"LC Chappell","year":"2019","unstructured":"Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019;394:849\u2013860","journal-title":"Lancet"},{"key":"10276_CR216","doi-asserted-by":"publisher","first-page":"e4949","DOI":"10.1097\/MD.0000000000004949","volume":"95","author":"X Kong","year":"2016","unstructured":"Kong X, Kong Y, Zhang F, et al. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: a meta-analysis (a prisma-compliant study). Medicine (Baltimore). 2016;95:e4949","journal-title":"Medicine (Baltimore)"},{"key":"10276_CR217","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2019.08.020","volume":"71","author":"E de Vries","year":"2019","unstructured":"de Vries E, Beuers U. Ursodeoxycholic acid in pregnancy. J Hepatol. 2019;71:1237\u20131245","journal-title":"J Hepatol"},{"key":"10276_CR218","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/gut.2010.228924","volume":"60","author":"BE Wellge","year":"2011","unstructured":"Wellge BE, Sterneck M, Teufel A, et al. Pregnancy in primary sclerosing cholangitis. Gut. 2011;60:1117\u20131121","journal-title":"Gut"},{"key":"10276_CR219","first-page":"188","volume":"34","author":"J Rudi","year":"1996","unstructured":"Rudi J, Sch\u00f6nig T, Stremmel W. Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy. Z Gastroenterol. 1996;34:188\u2013191","journal-title":"Z Gastroenterol"},{"key":"10276_CR220","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.dld.2010.06.002","volume":"42","author":"L V\u00edtek","year":"2010","unstructured":"V\u00edtek L, Zelenkov\u00e1 M, Br\u016fha R. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. Dig Liver Dis. 2010;42:911\u2013912","journal-title":"Dig Liver Dis"},{"key":"10276_CR221","first-page":"61","volume":"4","author":"N Al-Harthy","year":"2012","unstructured":"Al-Harthy N, Kumagi T. Natural history and management of primary biliary cirrhosis. Hepat Med. 2012;4:61\u201371","journal-title":"Hepat Med"},{"key":"10276_CR222","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0016-5085(80)90571-5","volume":"78","author":"E Christensen","year":"1980","unstructured":"Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology. 1980;78:236\u2013246","journal-title":"Gastroenterology"},{"key":"10276_CR223","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/hep.510230108","volume":"23","author":"GR Locke","year":"1996","unstructured":"Locke GR, Therneau TM, Ludwig J, et al. Time course of histological progression in primary biliary cirrhosis. Hepatology. 1996;23:52\u201356","journal-title":"Hepatology"},{"key":"10276_CR224","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1572-0241.1999.00770.x","volume":"94","author":"J Springer","year":"1999","unstructured":"Springer J, Cauch-Dudek K, O\u2019Rourke K, et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol. 1999;94:47\u201353","journal-title":"Am J Gastroenterol"},{"key":"10276_CR225","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M Prince","year":"2002","unstructured":"Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123:1044\u20131051","journal-title":"Gastroenterology"},{"key":"10276_CR226","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","volume":"17","author":"AC Cheung","year":"2019","unstructured":"Cheung AC, Lammers WJ, Murillo PCF, et al. Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol. 2019;17:2076-2084.e2","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10276_CR227","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/liv.12560","volume":"35","author":"C Quarneti","year":"2015","unstructured":"Quarneti C, Muratori P, Lalanne C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int. 2015;35:636\u2013641","journal-title":"Liver Int"},{"key":"10276_CR228","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jhep.2010.05.026","volume":"53","author":"DE Jones","year":"2010","unstructured":"Jones DE, Al-Rifai A, Frith J, et al. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol. 2010;53:911\u2013917","journal-title":"J Hepatol"},{"key":"10276_CR229","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/gut.2003.036558","volume":"54","author":"EI Rigopoulou","year":"2005","unstructured":"Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005;54:528\u2013532","journal-title":"Gut"},{"key":"10276_CR230","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/hep.21172","volume":"43","author":"J Wesierska-Gadek","year":"2006","unstructured":"Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006;43:1135\u20131144","journal-title":"Hepatology"},{"key":"10276_CR231","doi-asserted-by":"publisher","first-page":"9121207","DOI":"10.1155\/2019\/9121207","volume":"2019","author":"C Huang","year":"2019","unstructured":"Huang C, Han W, Wang C, et al. Early prognostic utility of Gp210 antibody-positive rate in primary biliary cholangitis: a meta-analysis. Dis Markers. 2019;2019:9121207","journal-title":"Dis Markers"},{"key":"10276_CR232","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3109\/08916934.2013.801461","volume":"46","author":"NK Gatselis","year":"2013","unstructured":"Gatselis NK, Zachou K, Norman GL, et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471\u2013479","journal-title":"Autoimmunity"},{"key":"10276_CR233","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM198301063080101","volume":"308","author":"J Roll","year":"1983","unstructured":"Roll J, Boyer JL, Barry D, et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983;308:1\u20137","journal-title":"N Engl J Med"},{"key":"10276_CR234","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/gut.49.2.276","volume":"49","author":"FP Vleggaar","year":"2001","unstructured":"Vleggaar FP, van Buuren HR, Zondervan PE, et al. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut. 2001;49:276\u2013281","journal-title":"Gut"},{"key":"10276_CR235","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/apt.15533","volume":"50","author":"PCF Murillo","year":"2019","unstructured":"Murillo PCF, Hirschfield GM, Corpechot C, et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther. 2019;50:1127\u20131136","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10276-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10276-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10276-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T17:52:12Z","timestamp":1700157132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10276-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":235,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10276"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10276-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This guidance were independently prepared and peer reviewed, and all contributors disclosed their conflicts of interest. Hong You, Xiong Ma, Cumali Efe, Guiqiang Wang, Sook\u2011Hyang Jeong, Kazumichi Abe, Weijia Duan,Sha Chen, Yuanyuan Kong, Dong Zhang, Lai Wei, Fu\u2011Sheng Wang, Han\u2011Chieh Lin, Jin Mo Yang,Tawesak Tanwandee, Rino A. Gani, Diana A. Payawal, Barjesh C. Sharma, Jinlin Hou,Osamu Yokosuka, A. Kadir Dokmeci, Darrell Crawford, Jia\u2011Horng Kao, Teerha Piratvisuth,Dong Jin Suh, Laurentius A. Lesmana, Jose Sollano, George Lau, Shiv K. Sarin, Masao Omata, Atsushi Tanaka, Jidong Jia these authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}